HDACs and HDAC inhibitors in cancer development and therapy
Over the last several decades, it has become clear that epigenetic abnormalities may be one
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …
Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective
ML Jin, KW Jeong - Experimental & Molecular Medicine, 2023 - nature.com
The development and immune evasion of cancer stem cells (CSCs) limit the efficacy of
currently available anticancer therapies. Recent studies have shown that epigenetic …
currently available anticancer therapies. Recent studies have shown that epigenetic …
Parthenolide promotes the repair of spinal cord injury by modulating M1/M2 polarization via the NF-κB and STAT 1/3 signaling pathway
T Gaojian, Q Dingfei, L Linwei, W Xiaowei… - Cell death …, 2020 - nature.com
Spinal cord injury (SCI) is a severe neurological disease; however, there is no effective
treatment for spinal cord injury. Neuroinflammation involves the activation of resident …
treatment for spinal cord injury. Neuroinflammation involves the activation of resident …
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
R Camicia, HC Winkler, PO Hassa - Molecular cancer, 2015 - Springer
Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy
and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest …
and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest …
Targeting histone deacetylases in idiopathic pulmonary fibrosis: a future therapeutic option
M Korfei, P Mahavadi, A Guenther - Cells, 2022 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited
therapeutic options, and there is a huge unmet need for new therapies. A growing body of …
therapeutic options, and there is a huge unmet need for new therapies. A growing body of …
Histone deacetylases as targets for treatment of multiple diseases
J Tang, H Yan, S Zhuang - Clinical science, 2013 - portlandpress.com
HDACs (histone deacetylases) are a group of enzymes that deacetylate histones as well as
non-histone proteins. They are known as modulators of gene transcription and are …
non-histone proteins. They are known as modulators of gene transcription and are …
STAT3 interactors as potential therapeutic targets for cancer treatment
F Laudisi, F Cherubini, G Monteleone… - International journal of …, 2018 - mdpi.com
Signal transducers and activators of transcription (STATs) mediate essential signaling
pathways in different biological processes, including immune responses, hematopoiesis …
pathways in different biological processes, including immune responses, hematopoiesis …
Regulation of STAT signaling by acetylation
S Zhuang - Cellular signalling, 2013 - Elsevier
Signal transducers and activators of transcription (STAT) belong to a family of latent
cytoplasmic factors that can be activated by tyrosine phosphorylation by the members of the …
cytoplasmic factors that can be activated by tyrosine phosphorylation by the members of the …
Ketogenic diet elicits antitumor properties through inducing oxidative stress, inhibiting MMP-9 expression, and rebalancing M1/M2 tumor-associated macrophage …
N Zhang, C Liu, L Jin, R Zhang, T Wang… - Journal of agricultural …, 2020 - ACS Publications
Many advanced cancers are characterized by metabolic disorders. A dietary therapeutic
strategy was proposed to inhibit tumor growth through administration of low-carbohydrate …
strategy was proposed to inhibit tumor growth through administration of low-carbohydrate …
Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer
Histone deacetylase (HDAC) inhibitors have demonstrated clinical benefits in subtypes of
hematological malignancies. However, the efficacy of HDAC inhibitors in solid tumors …
hematological malignancies. However, the efficacy of HDAC inhibitors in solid tumors …